ID   EPHA4_HUMAN             Reviewed;         986 AA.
AC   P54764; A8K2P1; B2R601; B7Z6Q8; Q2M380;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Ephrin type-A receptor 4;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like kinase 8;
DE            Short=EK8;
DE            Short=hEK8;
DE   AltName: Full=Tyrosine-protein kinase TYRO1;
DE   AltName: Full=Tyrosine-protein kinase receptor SEK;
DE   Flags: Precursor;
GN   Name=EPHA4; Synonyms=HEK8, SEK, TYRO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=7898931;
RA   Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M.,
RA   Basu R., Welcher A.A.;
RT   "cDNA cloning and tissue distribution of five human EPH-like receptor
RT   protein-tyrosine kinases.";
RL   Oncogene 10:897-905(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [6]
RP   INTERACTION WITH SIPA1L1.
RX   PubMed=18094260; DOI=10.1523/JNEUROSCI.2746-07.2007;
RA   Richter M., Murai K.K., Bourgin C., Pak D.T., Pasquale E.B.;
RT   "The EphA4 receptor regulates neuronal morphology through SPAR-
RT   mediated inactivation of Rap GTPases.";
RL   J. Neurosci. 27:14205-14215(2007).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF CDK5, AND AUTOPHOSPHORYLATION.
RX   PubMed=17143272; DOI=10.1038/nn1811;
RA   Fu W.Y., Chen Y., Sahin M., Zhao X.S., Shi L., Bikoff J.B., Lai K.O.,
RA   Yung W.H., Fu A.K., Greenberg M.E., Ip N.Y.;
RT   "Cdk5 regulates EphA4-mediated dendritic spine retraction through an
RT   ephexin1-dependent mechanism.";
RL   Nat. Neurosci. 10:67-76(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 29-209.
RX   PubMed=18708347; DOI=10.1074/jbc.M804114200;
RA   Qin H., Shi J., Noberini R., Pasquale E.B., Song J.;
RT   "Crystal structure and NMR binding reveal that two small molecule
RT   antagonists target the high affinity ephrin-binding channel of the
RT   EphA4 receptor.";
RL   J. Biol. Chem. 283:29473-29484(2008).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 30-202 IN COMPLEX WITH EFNA2
RP   OR EFNB2, AND LIGAND-BINDING.
RX   PubMed=19836338; DOI=10.1016/j.str.2009.07.018;
RA   Bowden T.A., Aricescu A.R., Nettleship J.E., Siebold C.,
RA   Rahman-Huq N., Owens R.J., Stuart D.I., Jones E.Y.;
RT   "Structural plasticity of EPH receptor A4 facilitates cross-class
RT   ephrin signaling.";
RL   Structure 17:1386-1397(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 29-203 IN COMPLEX WITH
RP   EFNB2, AND MUTAGENESIS OF GLN-40 AND GLU-42.
RX   PubMed=19875447; DOI=10.1074/jbc.M109.064824;
RA   Qin H., Noberini R., Huan X., Shi J., Pasquale E.B., Song J.;
RT   "Structural characterization of the EphA4-Ephrin-B2 complex reveals
RT   new features enabling Eph-ephrin binding promiscuity.";
RL   J. Biol. Chem. 285:644-654(2010).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-269; GLU-370 AND PHE-399.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds membrane-bound
CC       ephrin family ligands residing on adjacent cells, leading to
CC       contact-dependent bidirectional signaling into neighboring cells.
CC       The signaling pathway downstream of the receptor is referred to as
CC       forward signaling while the signaling pathway downstream of the
CC       ephrin ligand is referred to as reverse signaling. Highly
CC       promiscuous, it has the unique property among Eph receptors to
CC       bind and to be physiologically activated by both GPI-anchored
CC       ephrin-A and transmembrane ephrin-B ligands including EFNA1 and
CC       EFNB3. Upon activation by ephrin ligands, modulates cell
CC       morphology and integrin-dependent cell adhesion through regulation
CC       of the Rac, Rap and Rho GTPases activity. Plays an important role
CC       in the development of the nervous system controlling different
CC       steps of axonal guidance including the establishment of the
CC       corticospinal projections. May also control the segregation of
CC       motor and sensory axons during neuromuscular circuit development.
CC       In addition to its role in axonal guidance plays a role in
CC       synaptic plasticity. Activated by EFNA1 phosphorylates CDK5 at
CC       'Tyr-15' which in turn phosphorylates NGEF regulating RHOA and
CC       dendritic spine morphogenesis. In the nervous system, plays also a
CC       role in repair after injury preventing axonal regeneration and in
CC       angiogenesis playing a role in central nervous system vascular
CC       formation. Additionally, its promiscuity makes it available to
CC       participate in a variety of cell-cell signaling regulating for
CC       instance the development of the thymic epithelium.
CC       {ECO:0000269|PubMed:17143272}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses. Interacts (phosphorylated at position Tyr-602) with
CC       FYN. Interacts with CDK5, CDK5R1 and NGEF; upon activation by
CC       EFNA1 induces NGEF phosphorylation by the kinase CDK5. Interacts
CC       with CHN1; effector of EPHA4 in axon guidance linking EPHA4
CC       activation to RAC1 regulation (By similarity). Interacts (via PDZ
CC       motif) with SIPA1L1 (via PDZ domain); controls neuronal morphology
CC       through regulation of the RAP1 (RAP1A or RAP1B) and RAP2 (RAP2A,
CC       RAP2B or RAP2C) GTPases. {ECO:0000250,
CC       ECO:0000269|PubMed:18094260, ECO:0000269|PubMed:19836338,
CC       ECO:0000269|PubMed:19875447}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}. Cell projection, axon
CC       {ECO:0000250}. Cell projection, dendrite {ECO:0000250}. Cell
CC       junction, synapse, postsynaptic cell membrane, postsynaptic
CC       density {ECO:0000250}. Early endosome {ECO:0000250}.
CC       Note=Clustered upon activation and targeted to early endosome.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P54764-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54764-2; Sequence=VSP_056016;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The protein kinase domain mediates interaction with NGEF.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36645; AAA74246.1; -; mRNA.
DR   EMBL; AK290306; BAF82995.1; -; mRNA.
DR   EMBL; AK300772; BAH13344.1; -; mRNA.
DR   EMBL; AK312380; BAG35298.1; -; mRNA.
DR   EMBL; AC010899; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC105000; AAI05001.1; -; mRNA.
DR   EMBL; BC105002; AAI05003.1; -; mRNA.
DR   CCDS; CCDS2447.1; -. [P54764-1]
DR   PIR; I78844; I78844.
DR   RefSeq; NP_001291465.1; NM_001304536.1. [P54764-1]
DR   RefSeq; NP_001291466.1; NM_001304537.1. [P54764-2]
DR   RefSeq; NP_004429.1; NM_004438.4. [P54764-1]
DR   UniGene; Hs.371218; -.
DR   PDB; 2LW8; NMR; -; A=29-209.
DR   PDB; 2WO1; X-ray; 1.85 A; A/B=30-202.
DR   PDB; 2WO2; X-ray; 2.45 A; A=30-202.
DR   PDB; 2WO3; X-ray; 2.35 A; A=30-202.
DR   PDB; 3CKH; X-ray; 2.80 A; A/B=29-209.
DR   PDB; 3GXU; X-ray; 2.50 A; A=29-203.
DR   PDB; 4BK4; X-ray; 3.65 A; A/B=20-547.
DR   PDB; 4BK5; X-ray; 4.00 A; A=20-547.
DR   PDB; 4BKA; X-ray; 5.30 A; A=20-547.
DR   PDB; 4BKF; X-ray; 4.65 A; A/B=20-547.
DR   PDB; 4M4P; X-ray; 2.08 A; A=27-543.
DR   PDB; 4M4R; X-ray; 3.13 A; A/C/E/G=27-543.
DR   PDB; 4W4Z; X-ray; 2.41 A; A/B/C/D=29-204.
DR   PDB; 4W50; X-ray; 2.42 A; A/B/C/D=29-204.
DR   PDB; 5JR2; X-ray; 1.75 A; A/B/C/D=29-204.
DR   PDBsum; 2LW8; -.
DR   PDBsum; 2WO1; -.
DR   PDBsum; 2WO2; -.
DR   PDBsum; 2WO3; -.
DR   PDBsum; 3CKH; -.
DR   PDBsum; 3GXU; -.
DR   PDBsum; 4BK4; -.
DR   PDBsum; 4BK5; -.
DR   PDBsum; 4BKA; -.
DR   PDBsum; 4BKF; -.
DR   PDBsum; 4M4P; -.
DR   PDBsum; 4M4R; -.
DR   PDBsum; 4W4Z; -.
DR   PDBsum; 4W50; -.
DR   PDBsum; 5JR2; -.
DR   ProteinModelPortal; P54764; -.
DR   SMR; P54764; -.
DR   BioGrid; 108357; 39.
DR   DIP; DIP-48294N; -.
DR   IntAct; P54764; 2.
DR   STRING; 9606.ENSP00000281821; -.
DR   BindingDB; P54764; -.
DR   ChEMBL; CHEMBL3988; -.
DR   GuidetoPHARMACOLOGY; 1824; -.
DR   iPTMnet; P54764; -.
DR   PhosphoSitePlus; P54764; -.
DR   BioMuta; EPHA4; -.
DR   DMDM; 1711371; -.
DR   EPD; P54764; -.
DR   MaxQB; P54764; -.
DR   PaxDb; P54764; -.
DR   PeptideAtlas; P54764; -.
DR   PRIDE; P54764; -.
DR   TopDownProteomics; P54764-1; -. [P54764-1]
DR   DNASU; 2043; -.
DR   Ensembl; ENST00000281821; ENSP00000281821; ENSG00000116106. [P54764-1]
DR   Ensembl; ENST00000409938; ENSP00000386829; ENSG00000116106. [P54764-1]
DR   GeneID; 2043; -.
DR   KEGG; hsa:2043; -.
DR   UCSC; uc002vmq.4; human. [P54764-1]
DR   CTD; 2043; -.
DR   DisGeNET; 2043; -.
DR   GeneCards; EPHA4; -.
DR   HGNC; HGNC:3388; EPHA4.
DR   HPA; CAB028368; -.
DR   MalaCards; EPHA4; -.
DR   MIM; 602188; gene.
DR   neXtProt; NX_P54764; -.
DR   OpenTargets; ENSG00000116106; -.
DR   PharmGKB; PA27820; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P54764; -.
DR   KO; K05105; -.
DR   OMA; DWIPREG; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P54764; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54764; -.
DR   SIGNOR; P54764; -.
DR   ChiTaRS; EPHA4; human.
DR   EvolutionaryTrace; P54764; -.
DR   GeneWiki; EPH_receptor_A4; -.
DR   GenomeRNAi; 2043; -.
DR   PRO; PR:P54764; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000116106; -.
DR   CleanEx; HS_EPHA4; -.
DR   ExpressionAtlas; P54764; baseline and differential.
DR   Genevisible; P54764; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0044295; C:axonal growth cone; IEA:Ensembl.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0031901; C:early endosome membrane; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0030175; C:filopodium; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0097161; F:DH domain binding; IDA:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0042731; F:PH domain binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0021957; P:corticospinal tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB.
DR   GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB.
DR   GO; GO:0008347; P:glial cell migration; IEA:Ensembl.
DR   GO; GO:0008045; P:motor neuron axon guidance; ISS:UniProtKB.
DR   GO; GO:0048681; P:negative regulation of axon regeneration; ISS:UniProtKB.
DR   GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:2001108; P:positive regulation of Rho guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0048710; P:regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   CDD; cd10482; EphR_LBD_A4; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034270; EphA4_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell junction; Cell membrane; Cell projection; Complete proteome;
KW   Developmental protein; Endosome; Glycoprotein; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Repeat;
KW   Signal; Synapse; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    986       Ephrin type-A receptor 4.
FT                                /FTId=PRO_0000016807.
FT   TOPO_DOM     20    547       Extracellular. {ECO:0000255}.
FT   TRANSMEM    548    569       Helical. {ECO:0000255}.
FT   TOPO_DOM    570    986       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       30    209       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      328    439       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      440    537       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      621    882       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      911    975       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     627    635       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       984    986       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    191    325       Cys-rich.
FT   ACT_SITE    746    746       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     653    653       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     596    596       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     602    602       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     779    779       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     928    928       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000255}.
FT   CARBOHYD    235    235       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    545    545       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     53       MAGIFYFALFSCLFGICDAVTGSRVYPANEVTLLDSRSVQG
FT                                ELGWIASPLEGG -> MK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056016.
FT   VARIANT     269    269       R -> Q (in dbSNP:rs35084379).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042135.
FT   VARIANT     370    370       G -> E (in a bladder carcinoma NOS
FT                                sample; somatic mutation;
FT                                dbSNP:rs756952113).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042136.
FT   VARIANT     399    399       S -> F (in a metastatic melanoma sample;
FT                                somatic mutation; dbSNP:rs868224085).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042137.
FT   VARIANT     953    953       R -> K (in dbSNP:rs35341687).
FT                                /FTId=VAR_049721.
FT   MUTAGEN      40     40       Q->A: 10-fold reduced affinity for EFNB2;
FT                                when associated with A-42.
FT                                {ECO:0000269|PubMed:19875447}.
FT   MUTAGEN      42     42       E->A: 10-fold reduced affinity for EFNB2;
FT                                when associated with A-40.
FT                                {ECO:0000269|PubMed:19875447}.
FT   CONFLICT     71     71       Q -> P (in Ref. 2; BAF82995).
FT                                {ECO:0000305}.
FT   CONFLICT    102    102       K -> R (in Ref. 2; BAF82995).
FT                                {ECO:0000305}.
FT   CONFLICT    137    137       I -> V (in Ref. 2; BAG35298).
FT                                {ECO:0000305}.
FT   CONFLICT    362    362       Y -> H (in Ref. 2; BAF82995).
FT                                {ECO:0000305}.
FT   STRAND       30     35       {ECO:0000244|PDB:5JR2}.
FT   HELIX        36     38       {ECO:0000244|PDB:5JR2}.
FT   TURN         40     42       {ECO:0000244|PDB:4M4R}.
FT   STRAND       46     60       {ECO:0000244|PDB:5JR2}.
FT   STRAND       62     65       {ECO:0000244|PDB:2LW8}.
FT   STRAND       66     73       {ECO:0000244|PDB:5JR2}.
FT   STRAND       77     79       {ECO:0000244|PDB:5JR2}.
FT   STRAND       82     85       {ECO:0000244|PDB:5JR2}.
FT   STRAND       93     96       {ECO:0000244|PDB:2LW8}.
FT   STRAND       97    105       {ECO:0000244|PDB:5JR2}.
FT   HELIX       108    110       {ECO:0000244|PDB:5JR2}.
FT   TURN        115    117       {ECO:0000244|PDB:2WO1}.
FT   STRAND      120    130       {ECO:0000244|PDB:5JR2}.
FT   STRAND      131    133       {ECO:0000244|PDB:2LW8}.
FT   HELIX       139    141       {ECO:0000244|PDB:5JR2}.
FT   STRAND      143    149       {ECO:0000244|PDB:5JR2}.
FT   STRAND      154    158       {ECO:0000244|PDB:5JR2}.
FT   TURN        159    162       {ECO:0000244|PDB:4M4P}.
FT   STRAND      163    173       {ECO:0000244|PDB:5JR2}.
FT   STRAND      178    189       {ECO:0000244|PDB:5JR2}.
FT   STRAND      191    202       {ECO:0000244|PDB:5JR2}.
FT   STRAND      207    209       {ECO:0000244|PDB:4M4P}.
FT   STRAND      212    214       {ECO:0000244|PDB:4M4P}.
FT   STRAND      226    230       {ECO:0000244|PDB:4M4P}.
FT   STRAND      237    248       {ECO:0000244|PDB:4M4P}.
FT   STRAND      257    262       {ECO:0000244|PDB:4M4P}.
FT   STRAND      266    269       {ECO:0000244|PDB:4M4P}.
FT   STRAND      272    275       {ECO:0000244|PDB:4M4P}.
FT   STRAND      304    306       {ECO:0000244|PDB:4M4R}.
FT   STRAND      333    340       {ECO:0000244|PDB:4M4P}.
FT   STRAND      343    349       {ECO:0000244|PDB:4M4P}.
FT   STRAND      361    368       {ECO:0000244|PDB:4M4P}.
FT   TURN        373    375       {ECO:0000244|PDB:4M4R}.
FT   STRAND      385    388       {ECO:0000244|PDB:4M4P}.
FT   STRAND      390    393       {ECO:0000244|PDB:4M4P}.
FT   STRAND      395    401       {ECO:0000244|PDB:4M4P}.
FT   STRAND      405    416       {ECO:0000244|PDB:4M4P}.
FT   STRAND      418    423       {ECO:0000244|PDB:4M4P}.
FT   HELIX       426    428       {ECO:0000244|PDB:4M4P}.
FT   STRAND      429    435       {ECO:0000244|PDB:4M4P}.
FT   STRAND      447    452       {ECO:0000244|PDB:4M4P}.
FT   STRAND      457    461       {ECO:0000244|PDB:4M4P}.
FT   STRAND      473    483       {ECO:0000244|PDB:4M4P}.
FT   STRAND      489    500       {ECO:0000244|PDB:4M4P}.
FT   STRAND      508    517       {ECO:0000244|PDB:4M4P}.
FT   STRAND      528    531       {ECO:0000244|PDB:4M4P}.
FT   TURN        538    540       {ECO:0000244|PDB:4M4P}.
SQ   SEQUENCE   986 AA;  109860 MW;  0C39C1152EDDD46F CRC64;
     MAGIFYFALF SCLFGICDAV TGSRVYPANE VTLLDSRSVQ GELGWIASPL EGGWEEVSIM
     DEKNTPIRTY QVCNVMEPSQ NNWLRTDWIT REGAQRVYIE IKFTLRDCNS LPGVMGTCKE
     TFNLYYYESD NDKERFIREN QFVKIDTIAA DESFTQVDIG DRIMKLNTEI RDVGPLSKKG
     FYLAFQDVGA CIALVSVRVF YKKCPLTVRN LAQFPDTITG ADTSSLVEVR GSCVNNSEEK
     DVPKMYCGAD GEWLVPIGNC LCNAGHEERS GECQACKIGY YKALSTDATC AKCPPHSYSV
     WEGATSCTCD RGFFRADNDA ASMPCTRPPS APLNLISNVN ETSVNLEWSS PQNTGGRQDI
     SYNVVCKKCG AGDPSKCRPC GSGVHYTPQQ NGLKTTKVSI TDLLAHTNYT FEIWAVNGVS
     KYNPNPDQSV SVTVTTNQAA PSSIALVQAK EVTRYSVALA WLEPDRPNGV ILEYEVKYYE
     KDQNERSYRI VRTAARNTDI KGLNPLTSYV FHVRARTAAG YGDFSEPLEV TTNTVPSRII
     GDGANSTVLL VSVSGSVVLV VILIAAFVIS RRRSKYSKAK QEADEEKHLN QGVRTYVDPF
     TYEDPNQAVR EFAKEIDASC IKIEKVIGVG EFGEVCSGRL KVPGKREICV AIKTLKAGYT
     DKQRRDFLSE ASIMGQFDHP NIIHLEGVVT KCKPVMIITE YMENGSLDAF LRKNDGRFTV
     IQLVGMLRGI GSGMKYLSDM SYVHRDLAAR NILVNSNLVC KVSDFGMSRV LEDDPEAAYT
     TRGGKIPIRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSY GERPYWDMSN QDVIKAIEEG
     YRLPPPMDCP IALHQLMLDC WQKERSDRPK FGQIVNMLDK LIRNPNSLKR TGTESSRPNT
     ALLDPSSPEF SAVVSVGDWL QAIKMDRYKD NFTAAGYTTL EAVVHVNQED LARIGITAIT
     HQNKILSSVQ AMRTQMQQMH GRMVPV
//
